Developer docs
API playgroundTry for free, no card

Search company profiles

Pathway Labs

Full company profile

uuid02lw7il

Namestring
Pathway Labs
Legal namestring
Pathway Labs
Websiteurl
pathwaylabs.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Pathway Labs is a privately held, U.S.-based healthcare AI company whose core product, EchoNext, is an FDA-cleared (510(k), June 22, 2026) deep learning system that analyzes standard 12-lead electrocardiograms to identify patients likely to have structural heart disease, including LV and RV systolic dysfunction, aortic and mitral regurgitation, aortic stenosis, tricuspid and pulmonic regurgitation, severe LV hypertrophy, pulmonary hypertension, and pericardial effusion. The platform ingests existing ECG waveforms without requiring new hardware, runs AI inference enterprise-wide with routing to individual physicians and clinical champions, and embeds results into existing cardiology workflows to coordinate diagnosis and treatment for high-risk patients. The company has deployed EchoNext at 20 hospitals and tested 500,000+ patients, reporting a 91% increase in new clinically significant diagnoses, and its Nature 2025 paper is the most-read cardiac AI paper of all time.

The company operates a B2B enterprise licensing model targeting health systems, cardiology departments, and primary care, with direct field sales driven through a website-based partnership inquiry form and no publicly disclosed pricing. Pathway Labs raised $8.5 million in funding in June 2026 from AlleyCorp and Breyer Capital to expand deployment, and on the same day as FDA clearance announced a partnership with OpenEvidence to broaden distribution across health systems. Underlying scientific credibility is reinforced by peer-reviewed publications across Nature, Nature Medicine, NEJM AI, JACC, European Heart Journal, JAMA, and Circulation.

Short descriptiontext

Pathway Labs develops EchoNext, an FDA-cleared AI tool that analyzes standard 12-lead ECGs to detect structural heart disease early. It licenses the platform to health systems and has deployed across 20 hospitals with 500K+ patients tested.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
Markets served

Serves global market

Keyword5 values
AI cardiac diagnostics, ECG analysis software, structural heart disease detection, clinical decision support, healthcare AI platform
Industry3 codes
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLACAGAG
Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
AI Cardiac Diagnostics Software
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Enterprise Healthcare Licensing
TypeSubscription Recurring
Description

B2B licensing model targeting health systems for deployment of EchoNext AI tool. Health systems initiate contact through partnership inquiry form. Pricing not publicly disclosed, suggesting enterprise quote-based model.

pathwaylabs.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1EchoNext
Description

AI-powered cardiac biomarker tool that reads standard 12-lead ECGs to detect structural heart disease including LV systolic dysfunction, RV systolic dysfunction, aortic stenosis, aortic regurgitation, mitral regurgitation, tricuspid regurgitation, pulmonic regurgitation, severe left ventricular hypertrophy, pulmonary hypertension, and pericardial effusion.

pathwaylabs.com
Core offering1 text field

Pathway Labs develops and sells EchoNext, an FDA-cleared AI tool that analyzes standard 12-lead ECG data to detect hidden structural heart disease and surface high-risk patients for follow-up. It is deployed at the enterprise level across health systems without requiring new hardware, with AI inference, physician routing, and care coordination built into existing cardiology workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 91% increase in new clinically significant diagnoses
+4 more records
Product overview1 text field

Pathway Labs offers a single unified product, EchoNext, an FDA-cleared AI system that detects structural heart disease from standard 12-lead ECGs. The system works by receiving standard ECG data, running AI inference instantaneously across health systems, and routing results to individual physicians and care teams. EchoNext enables centralized coordination to ensure high-risk patients receive diagnosis and treatment, with no hardware changes required.

Product and service1 record
1EchoNext
CategoryAI cardiac diagnostics software
Description

FDA-cleared AI tool that reads standard 12-lead ECGs to detect structural heart disease, including LV systolic dysfunction, RV systolic dysfunction, aortic stenosis, aortic regurgitation, mitral regurgitation, tricuspid regurgitation, pulmonic regurgitation, severe left ventricular hypertrophy, pulmonary hypertension, and pericardial effusion. Deployed at the enterprise level across health systems, routing AI-inferred results to individual physicians and system champions with minimal IT integration and no new hardware required. Targeted at health systems, cardiology departments, and primary care.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-22
Description

Pathway Labs is partnering with OpenEvidence to expand EchoNext into more health systems. OpenEvidence is an AI-powered medical information platform. The partnership enables broader distribution and integration of the cardiac AI diagnostic tool across healthcare networks.

2Press and Media Partners
Strategic tierMinorTypeGTM or Marketing Partner
Description

Featured and covered by leading medical and general news outlets including Nature, The New York Times, NEJM AI, Nature Medicine, JACC, JAMA, European Heart Journal, Circulation, Reuters, STAT, CNN, and Becker's Hospital Review.

pathwaylabs.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Anumana (Mayo Clinic Platform spinout) develops AI algorithms applied to ECG signals to detect cardiac conditions including structural heart disease, making it a direct clinical and technical peer to EchoNext.

TypeDirect peer
Description

HeartFlow provides AI-based FFR-CT analysis for coronary disease and is now expanding into broader structural heart assessment; comparable in regulatory pathway, evidence strategy, and health-system commercial model.

TypeBroad incumbent
Description

GE HealthCare is a broad incumbent in cardiac diagnostics and imaging, now including Caption Health AI; it competes for ECG and echo AI budgets and could bundle competing structural-heart AI capabilities into its enterprise contracts.

TypeDirect peer
Description

Ultromics develops AI-based echocardiography analysis to support diagnosis of conditions including heart failure and valve disease, making it a direct clinical peer focused on the same structural-heart detection Pathway targets.

TypeDirect peer
Description

Eko Health combines connected stethoscopes and digital ECG devices with AI cardiac analysis (SENSORA) for clinicians, overlapping directly with EchoNext on AI-driven cardiac detection from standard ECG inputs.

6Tempus Labs
TypeBroad incumbent
Description

Tempus is a large AI-driven precision medicine platform with growing cardiovascular offerings; it competes for the same enterprise health-system AI budgets and clinical leadership attention as Pathway Labs.

TypeDirect peer
Description

AliveCor (KardiaMobile/KardiaStation) builds FDA-cleared AI that interprets consumer and clinical ECGs for arrhythmias; it is the closest direct competitor to EchoNext's AI-on-ECG positioning, with overlap in health-system enterprise deployment.

TypeDirect peer
Description

Idoven offers an AI cloud platform that analyses continuous ambulatory ECG data to surface cardiac arrhythmias and structural abnormalities, closely comparable in technology and target customer base to EchoNext.

TypeDirect peer
Description

Cleerly applies AI to cardiac CT angiography to identify coronary artery disease; it is a peer in AI-driven cardiac diagnostics with overlapping health-system enterprise buyers and a similar reimbursement/clinical-evidence narrative.

10Caption Health (GE HealthCare)
TypeDirect peer
Description

Caption Health (acquired by GE HealthCare) provides FDA-cleared AI for cardiac ultrasound interpretation; it is a direct peer in the AI-enabled cardiac diagnostics category that health systems buy alongside EchoNext.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pathway Labs

AI Cardiac Diagnostics Softwarepathwaylabs.com

Pathway Labs develops EchoNext, an FDA-cleared AI tool that analyzes standard 12-lead ECGs to detect structural heart disease early. It licenses the platform to health systems and has deployed across 20 hospitals with 500K+ patients tested.

What Pathway Labs does

Pathway Labs is a privately held, U.S.-based healthcare AI company whose core product, EchoNext, is an FDA-cleared (510(k), June 22, 2026) deep learning system that analyzes standard 12-lead electrocardiograms to identify patients likely to have structural heart disease, including LV and RV systolic dysfunction, aortic and mitral regurgitation, aortic stenosis, tricuspid and pulmonic regurgitation, severe LV hypertrophy, pulmonary hypertension, and pericardial effusion. The platform ingests existing ECG waveforms without requiring new hardware, runs AI inference enterprise-wide with routing to individual physicians and clinical champions, and embeds results into existing cardiology workflows to coordinate diagnosis and treatment for high-risk patients. The company has deployed EchoNext at 20 hospitals and tested 500,000+ patients, reporting a 91% increase in new clinically significant diagnoses, and its Nature 2025 paper is the most-read cardiac AI paper of all time.

The company operates a B2B enterprise licensing model targeting health systems, cardiology departments, and primary care, with direct field sales driven through a website-based partnership inquiry form and no publicly disclosed pricing. Pathway Labs raised $8.5 million in funding in June 2026 from AlleyCorp and Breyer Capital to expand deployment, and on the same day as FDA clearance announced a partnership with OpenEvidence to broaden distribution across health systems. Underlying scientific credibility is reinforced by peer-reviewed publications across Nature, Nature Medicine, NEJM AI, JACC, European Heart Journal, JAMA, and Circulation.

Pathway Labs firmographics

Firmographics
Name
Pathway Labs
Legal name
Pathway Labs
Website
https://pathwaylabs.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Pathway Labs develops EchoNext, an FDA-cleared AI tool that analyzes standard 12-lead ECGs to detect structural heart disease early. It licenses the platform to health systems and has deployed across 20 hospitals with 500K+ patients tested.
Ownership category
akta.pro rank

Pathway Labs industry classification

Industry
Product category
AI Cardiac Diagnostics Software
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLACAGAG
Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • AI cardiac diagnostics
  • ECG analysis software
  • Structural heart disease detection
  • Clinical decision support
  • Healthcare AI platform

Pathway Labs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Enterprise Healthcare Licensing: B2B licensing model targeting health systems for deployment of EchoNext AI tool. Health systems initiate contact through partnership inquiry form. Pricing not publicly disclosed, suggesting enterprise quote-based model.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Pathway Labs product offering

Product offering

Core offering

Pathway Labs develops and sells EchoNext, an FDA-cleared AI tool that analyzes standard 12-lead ECG data to detect hidden structural heart disease and surface high-risk patients for follow-up. It is deployed at the enterprise level across health systems without requiring new hardware, with AI inference, physician routing, and care coordination built into existing cardiology workflows.

Product overview

Pathway Labs offers a single unified product, EchoNext, an FDA-cleared AI system that detects structural heart disease from standard 12-lead ECGs. The system works by receiving standard ECG data, running AI inference instantaneously across health systems, and routing results to individual physicians and care teams. EchoNext enables centralized coordination to ensure high-risk patients receive diagnosis and treatment, with no hardware changes required.

Differentiator

Problem solved

Functional benefit

Brands

  • EchoNext: AI-powered cardiac biomarker tool that reads standard 12-lead ECGs to detect structural heart disease including LV systolic dysfunction, RV systolic dysfunction, aortic stenosis, aortic regurgitation, mitral regurgitation, tricuspid regurgitation, pulmonic regurgitation, severe left ventricular hypertrophy, pulmonary hypertension, and pericardial effusion.

Products and services

  • EchoNext FDA-cleared AI tool that reads standard 12-lead ECGs to detect structural heart disease, including LV systolic dysfunction, RV systolic dysfunction, aortic stenosis, aortic regurgitation, mitral regurgitation, tricuspid regurgitation, pulmonic regurgitation, severe left ventricular hypertrophy, pulmonary hypertension, and pericardial effusion. Deployed at the enterprise level across health systems, routing AI-inferred results to individual physicians and system champions with minimal IT integration and no new hardware required. Targeted at health systems, cardiology departments, and primary care.

Quantifiable outcome

  • 91% increase in new clinically significant diagnoses
  • +4 more outcomes

Companies that use Pathway Labs

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Pathway Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Pathway Labs partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • OpenEvidencecoreTechnology or Integration · 22 June 2026Pathway Labs is partnering with OpenEvidence to expand EchoNext into more health systems. OpenEvidence is an AI-powered medical information platform. The partnership enables broader distribution and integration of the cardiac AI diagnostic tool across healthcare networks.
  • Press and Media PartnersminorGTM or Marketing PartnerFeatured and covered by leading medical and general news outlets including Nature, The New York Times, NEJM AI, Nature Medicine, JACC, JAMA, European Heart Journal, Circulation, Reuters, STAT, CNN, and Becker's Hospital Review.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Pathway Labs competitors and assessment

Company assessment

Direct peers

  • Anumana: Anumana (Mayo Clinic Platform spinout) develops AI algorithms applied to ECG signals to detect cardiac conditions including structural heart disease, making it a direct clinical and technical peer to EchoNext.
  • HeartFlow: HeartFlow provides AI-based FFR-CT analysis for coronary disease and is now expanding into broader structural heart assessment; comparable in regulatory pathway, evidence strategy, and health-system commercial model.
  • Ultromics: Ultromics develops AI-based echocardiography analysis to support diagnosis of conditions including heart failure and valve disease, making it a direct clinical peer focused on the same structural-heart detection Pathway targets.
  • Eko Health: Eko Health combines connected stethoscopes and digital ECG devices with AI cardiac analysis (SENSORA) for clinicians, overlapping directly with EchoNext on AI-driven cardiac detection from standard ECG inputs.
  • AliveCor: AliveCor (KardiaMobile/KardiaStation) builds FDA-cleared AI that interprets consumer and clinical ECGs for arrhythmias; it is the closest direct competitor to EchoNext's AI-on-ECG positioning, with overlap in health-system enterprise deployment.
  • Idoven: Idoven offers an AI cloud platform that analyses continuous ambulatory ECG data to surface cardiac arrhythmias and structural abnormalities, closely comparable in technology and target customer base to EchoNext.
  • Cleerly: Cleerly applies AI to cardiac CT angiography to identify coronary artery disease; it is a peer in AI-driven cardiac diagnostics with overlapping health-system enterprise buyers and a similar reimbursement/clinical-evidence narrative.
  • Caption Health (GE HealthCare): Caption Health (acquired by GE HealthCare) provides FDA-cleared AI for cardiac ultrasound interpretation; it is a direct peer in the AI-enabled cardiac diagnostics category that health systems buy alongside EchoNext.

Broad incumbents

  • GE HealthCare: GE HealthCare is a broad incumbent in cardiac diagnostics and imaging, now including Caption Health AI; it competes for ECG and echo AI budgets and could bundle competing structural-heart AI capabilities into its enterprise contracts.
  • Tempus Labs: Tempus is a large AI-driven precision medicine platform with growing cardiovascular offerings; it competes for the same enterprise health-system AI budgets and clinical leadership attention as Pathway Labs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Pathway Labs compliance and trust

Trust signal

Compliance1 record

Pathway Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pathway Labs leadership team

Management profile

Number of profiles

Pathway Labs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pathway Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pathway Labs

What does Pathway Labs do?

Pathway Labs develops and sells EchoNext, an FDA-cleared AI tool that analyzes standard 12-lead ECG data to detect hidden structural heart disease and surface high-risk patients for follow-up. It is deployed at the enterprise level across health systems without requiring new hardware, with AI inference, physician routing, and care coordination built into existing cardiology workflows.

Is Pathway Labs a public or private company?

Pathway Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pathway Labs founded?

Pathway Labs was founded in -1. It employs 1 to 10 people.

How does Pathway Labs make money?

One revenue line is on record: enterprise Healthcare Licensing.

Who are Pathway Labs's main competitors?

Direct peers on record are Anumana, HeartFlow, Ultromics, Eko Health, AliveCor, Idoven, Cleerly and Caption Health (GE HealthCare). Broad incumbents are GE HealthCare and Tempus Labs.

Does Pathway Labs have an API?

No public API is recorded for Pathway Labs.

What industry is Pathway Labs in?

Pathway Labs's product category is AI Cardiac Diagnostics Software. Its primary akta.pro industry code is HLAHAFAI, Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT), with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals